Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
The purpose of this study is to evaluate long-term safety,tolerability and blood pressure
 effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be
 given alone or in combination with other drugs that are commonly used in the treatment of
 hypertension
Approximately 50 million Americans have hypertension defined as a systolic blood pressure
 (SBP) greater then or equal to 140 mmHg and/or a diastolic blood pressure (DBP) greater then
 or equal to 90 mmHg. To control blood pressure, more than 2 agents are required in many
 patients. The current study is a randomized, titration-to-effect, open-label, multi center
 study. Patients will be randomized to either nebivolol or metoprolol. The dose of the
 randomized treatment can be titrated as needed to achieve blood pressure control. If
 necessary, additional antihypertensive agents (calcium antagonist, diuretic, etc.) can be
 added to achieve control. Patients will be seen every 1-3 months for approximately 18 months
 to assess long-term safety, tolerability and effectiveness of nebivolol versus metoprolol.
Inclusion Criteria:

 -  Completion of previous nebivolol study

 -  Stage 1-2 HTN at baseline of first study

 Exclusion Criteria:

 -  Recent myocardial infarction or stroke

 -  Contraindications to beta blocker therapy